FDA Determines Regulatory Review Period for BREO ELLIPTA Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of BREO ELLIPTA, following a submission to the US Patent and Trademark Office (USPTO) for the extension of a patent claiming the human drug product.